Aptinyx (APTX) Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" APTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APTX, but not buy additional shares or sell existing shares.
View APTX analyst ratings or view top-rated stocks.

8 equities research analysts have issued 1-year price targets for Aptinyx's shares. Their APTX share price forecasts range from $0.50 to $2.00. On average, they expect the company's stock price to reach $1.38 in the next year. This suggests a possible upside of 1,827.1% from the stock's current price.
View analysts price targets for APTX or view top-rated stocks among Wall Street analysts.

Aptinyx's stock was trading at $0.2853 on January 1st, 2023. Since then, APTX stock has decreased by 75.0% and is now trading at $0.0714.
View the best growth stocks for 2023 here.

Aptinyx saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 1,300,000 shares, a drop of 41.7% from the April 30th total of 2,230,000 shares. Based on an average trading volume of 4,450,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 2.9% of the shares of the company are sold short.
View Aptinyx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our APTX earnings forecast.

Aptinyx Inc. (NASDAQ:APTX) issued its earnings results on Thursday, March, 30th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Kadmon (KDMN), Matinas BioPharma (MTNB), Cidara Therapeutics (CDTX), ADMA Biologics (ADMA), DURECT (DRRX) and Catalyst Pharmaceuticals (CPRX).

(APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Aptinyx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.67%), Acadian Asset Management LLC (0.56%), Virtu Financial LLC (0.41%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Ashish Khanna, Bain Capital Life Sciences Inv, Joan W Miller, Norbert G Riedel and Robert J Hombach.
View institutional ownership trends.

Shares of APTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APTX stock can currently be purchased for approximately $0.07.

Aptinyx (NASDAQ:APTX) has a market capitalization of $4.83 million and generates $1 million in revenue each year. The company earns $-64,850,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The official website for the company is www.aptinyx.com. The company can be reached via phone at (847) 871-0377 or via email at investors@aptinyx.com.